This story originally ran on March 4.
A new company, Ubiquigent, has been formed to develop reagents and kits to help "advance understanding of the biology of the ubiquitin proteasome pathway."
Based in Dundee, Scotland, Ubiquigent is operating as a subsidiary of stem cell firm Stemgent, which plans to invest $4.5 million into Ubiquigent over the next three years.
Stemgent is based in Boston and San Diego. Ubiquigent is Stemgent's first overseas company.